Voyager to Present at Upcoming Investor Conferences LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026: Fireside chat at 1:00 p.m. ET on Wednesday, February 11, 2026, in New York, NY.Oppenheimer 36th Annual Healthcare Life Sciences Conference: Fireside chat at 3:20 p.m. ET on Thursday, February 26, 2026.TD Cowen ...
Southern Silver has been re-initiated with coverage, supported by a portfolio of four polymetallic projects in Mexico and the U.S., led by the flagship Cerro Las Minitas (CLM). CLM hosts a large 303 Moz AgEq resource and a 2024 PEA outlining robust economics (after-tax NPV5% of US$931M, 31% IRR), yet the company trades at only 10% of its NPV. Electrum Global Holdings owns 20.46% of SSV, adding strategic backing. CLM offers strong resource expansion potential, with a 12,000 m drill program underw...
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to dis...
Voyager Reports Third Quarter 2025 Financial and Operating Results - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today repo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.